Company Overview and News

21
Market Live: Nifty struggles below 10,800; Jhunjhunwala says 2018 is the year of consolidation

19h moneycontrol
KNR in focus: In a clarification note to the exchanges regarding "Promoters of Company taking large interest free loan from the Company", KNR Constructions said the promoters have extended unsecured loan of Rs 214.08 crore to the company, at the interest rate of 8.45 percent per annum to defray the term loan of one of the SPV. "There are no loans and advances given by the Company to promoters."
OPTOCIRCUI 500325 RELIANCE IDBI 539254 533155 JUBLFOOD 511288 CMQMY RIGD JBLWY CUMMINSIND HDFCBANK 500378 RLNIY SBAZ ADANITRANS GRUH INDIGO 500116 534690 IBN GRHFY 532942 539207 539448 KNRCON 500480 ICICIBANK LAKSHVILAS HDB 532174 500180 JINDALSAW 532391 MANPASAND

12
Market Live: Sensex consolidates amid global trade war fears; ICICI Bank, RIL most active

21h moneycontrol
India signs MOUs for early adoption of 5G: India signed three memoranda of understanding with three top UK academic institutions to facilitate meaningful exploration and early adoption of 5G technology.
GRUH OPTOCIRCUI INDIGO 500116 IBN IDBI 539254 GRHFY 533155 JUBLFOOD 511288 539448 500480 ICICIBANK CMQMY 532174 JINDALSAW JBLWY 532391 CUMMINSIND 500378 SBAZ ADANITRANS

12
Market Live: Sensex opens up 100 pts, Nifty nears 10,800; ICICI Bank, InterGlobe rally

22h moneycontrol
Rupee Update: The rupee slipped 12 paise to 68.20 against the US dollar due to fresh buying of the American currency by importers amid sustained foreign fund outflows. Forex dealers said the dollar hovering near an 11-month high against a basket of currencies overseas, supported by a rise in US yields, also weighed on the rupee but a higher opening of the domestic equity markets limited the fall. Foreign portfolio investors (FPIs) sold shares worth Rs 2,442.
GRUH OPTOCIRCUI INDIGO 500116 IBN IDBI 539254 GRHFY 533155 JUBLFOOD 511288 539448 500480 ICICIBANK CMQMY 532174 JINDALSAW JBLWY 532391 CUMMINSIND 500378 SBAZ ADANITRANS

7
Adani Transmission acquires 100% equity in Ghatampur SPV

2018-06-20 moneycontrol
Adani Transmission said that it has acquired 100 percent equity in share capital of Ghatampur Transmission Ltd (GTL) yesterday, which will set up 900 circuit Km transmission line to primarily evacuate power from 3X660MW Ghatampur Thermal Power Project.
ICICIBANK 532174 IBN 539254 ADANITRANS

0
Adani Transmission rises 3% on LoI for transmission project in Uttar Pradesh

2018-06-14 moneycontrol
Shares of Adani Transmission rose more than 3 percent in the opening trade on Thursday as company received LoI intra state transmission project in Uttar Pradesh.
539254 532955 RECLTD ADANITRANS

0
The Maharashtra Electricity Regulatory Commission reserves order on RInfra-Adani deal

2018-06-14 moneycontrol
The Maharashtra Electricity Regulatory Commission (MERC) today concluded its hearing on the proposed sale of Reliance Infrastructure's Mumbai power distribution business to Adani Transmission for an estimated Rs 18,800 crore.
500390 RELINFRA RELEY RIFS 539254 RIFA RELFF ADANITRANS

0
Merc reserves order on Reliance Infra-Adani Transmission deal

2018-06-14 freepressjournal.in
Mumbai: The Maharashtra Electricity Regulatory Commission (Merc) today concluded its hearing on the proposed sale of Reliance Infrastructure’s Mumbai power distribution business to Adani Transmission for an estimated Rs 18,800 crore.
500390 RELINFRA RELEY RIFS 539254 RIFA RELFF ADANITRANS

0
Adani Transmission Limited - Press Release

2018-06-13 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539254 ADANITRANS

0
Adani Transmission (₹131.2): Sell

2018-06-05 premium.thehindubusinessline
The stock has been in a medium-term downtrend since recording a new high at ₹252 in late January. While trending down, the stock decisively breached a key support at ₹175 in late April. Since then, the stock has been in a short-term downtrend. The stock trades well below its 50- and 200-day moving averages.
539254 ADANITRANS

0
Adani Transmission Limited - Updates

2018-05-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539254 ADANITRANS

0
Adani Transmission Limited - Outcome of Board Meeting

2018-05-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539254 ADANITRANS

0
Adani Transmission Limited - Financial Result Updates

2018-05-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
539254 ADANITRANS

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

1h - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2h - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...